liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Cost-effectiveness of iodixanol in patients at high risk of contrast-induced nephropathy
Department of Radiology, Karolinska University Hospital, Huddinge, Sweden, Department of Radiology, Karolinska Univ. Hospital Huddinge, S-141 86 Stockholm, Sweden.
Department of Cardiology, Ctr. Hosp. Universitaire Bichat, Paris, France.
Linköping University, Faculty of Health Sciences. Linköping University, Department of Medicine and Care. Östergötlands Läns Landsting, Heart Centre, Department of Cardiology.
Department of Cardiology, Heart Center, University of Technology, Dresden, Germany.
Show others and affiliations
2005 (English)In: American Heart Journal, ISSN 0002-8703, Vol. 149, no 2, 298-303 p.Article, review/survey (Refereed) Published
Abstract [en]

Background: Acute renal failure after contrast-induced nephropathy is a clinically important and costly complication after the use of iodine-based contrast media. We investigated the cost and cost-effectiveness of 2 contrast media in patients at high risk of contrast-induced nephropathy. Methods: The analyses were based on a randomized, prospective, multinational clinical study comparing the nephrotoxic effects of an isosmolar nonionic contrast medium, iodixanol, with those of a low-osmolar nonionic contrast medium, iohexol. Resource utilization data were obtained from the study and from a retrospective review of patients' hospital records. Swedish, German, and French unit prices were applied to resources used. Between-group differences in average costs were analyzed using a nonparametric bootstrap method. Results: Resource utilization data for 125 patients were analyzed. Seven contrast media-related serious adverse reactions, of which 6 were acute renal failures, were noted in 6 patients receiving iohexol. Two patients in the iodixanol group had 1 nonserious reaction each. The mean hospitalization cost per patient was €489, €573, and €393 lower after iodixanol than after iohexol using Swedish, German, and French unit prices, respectively. The mean per-patient costs of treating adverse drug reactions were €371, €399, and €445 lower after iodixanol than after iohexol, using the respective unit prices (P = 0.01). Iodixanol was cost-effective compared with iohexol, with both lower costs and better effects related to fewer adverse drug reactions. Conclusions: The isosmolar contrast medium iodixanol appears to be cost-effective when compared with a low-osmolar contrast medium, iohexol, in diabetic patients with renal impairment undergoing angiography. © 2005, Elsevier Inc. All rights reserved.

Place, publisher, year, edition, pages
2005. Vol. 149, no 2, 298-303 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-45524DOI: 10.1016/j.ahj.2004.07.020OAI: diva2:266420
Available from: 2009-10-11 Created: 2009-10-11 Last updated: 2011-01-12

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Fransson, Sven Göran
By organisation
Faculty of Health SciencesDepartment of Medicine and CareDepartment of Cardiology
In the same journal
American Heart Journal
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 62 hits
ReferencesLink to record
Permanent link

Direct link